Drug Trial Radar · NCT06777238
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
274
Actual
Start
Feb 24, 2025
Primary completion
Jul 30, 2026
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
GZR18Drug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome MeasureTime frame: Baseline, Week 44
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.